Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer…
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in…